Evidence map›Paper›PMID 31156624›Full record

ArticleFrontiers in immunology2019

Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients.

Helena Idborg, Arash Zandian, Elena Ossipova, Edvard Wigren, Charlotta Preger, Fariborz Mobarrez, Antonio Checa, Azita Sohrabian, Pascal Pucholt, Johanna K Sandling and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

Helena IdborgDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Arash ZandianSciLifeLab, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Elena OssipovaDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Edvard WigrenDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Charlotta PregerDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Fariborz MobarrezDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Antonio ChecaDivision of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Azita SohrabianDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Pascal PucholtDepartment of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.
Johanna K SandlingDepartment of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.
Cátia Fernandes-CerqueiraDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Johan RönnelidDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Vilija OkeDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Giorgia GrossoDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Marika KvarnströmDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Anders LarssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Craig E WheelockDivision of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Ann-Christine SyvänenDepartment of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Lars RönnblomDepartment of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.
Kim KultimaDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Helena PerssonScience for Life Laboratory, Drug Discovery and Development & School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.
Susanne GräslundDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Iva GunnarssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Peter NilssonSciLifeLab, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Elisabet SvenungssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Per-Johan JakobssonDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Karolinska Institutet · SEUppsala University · SEKarolinska University Hospital · SEKTH Royal Institute of Technology · SEScience for Life Laboratory · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease, which currently lacks specific diagnostic biomarkers. The diversity within the patients obstructs clinical trials but may also reflect differences in underlying pathogenesis. Our objective was to obtain protein profiles to identify potential general biomarkers of SLE and to determine molecular subgroups within SLE for patient stratification. Plasma samples from a cross-sectional study of well-characterized SLE patients (

Indexed as

AdultBiomarkersCluster AnalysisCross-Sectional StudiesFemaleHumansInterferon Regulatory FactorsLupus Erythematosus, SystemicMaleMiddle AgedOrganic Cation Transporter 2PhenotypeProteomicsProto-Oncogene Proteins c-etsS100A12 ProteinBiomarkersInterferon Regulatory FactorsIRF5 protein, humanOrganic Cation Transporter 2Proto-Oncogene Proteins c-etsS100A12 ProteinSPDEF protein, humanantibody suspension bead arraysbiomarker discoveryhierarchical clusteringInterferon regulating factor 5 (IRF5)plasma proteomicsSLE - Systemic Lupus Erythematoussubgroupsunsupervised clustering

Identifiers

PMID31156624
PMCPMC6533644
OpenAlexW2946411578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.